hekblue detection medium (InvivoGen)
Structured Review

Hekblue Detection Medium, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 606 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hekblue+detection+medium/HEK-Blue+Detection/pm37894949-329-34-37
Average 97 stars, based on 606 article reviews
Images
1) Product Images from "Necrotic Cells from Head and Neck Carcinomas Release Biomolecules That Are Activating Toll-like Receptor 3."
Article Title: Necrotic Cells from Head and Neck Carcinomas Release Biomolecules That Are Activating Toll-like Receptor 3.
Journal: International journal of molecular sciences
doi: 10.3390/ijms242015269
Figure Legend Snippet: Figure 1. Flow chart showing the experimental design of the study. Conditioned media were collected from cells stressed with irradiation, serum starvation, hypoxia and oxidative stress. In addition, extracellular vesicles were isolated from conditioned media of irradiated cells. Both crude conditioned media and isolated extracellular vesicles were used to stimulate HEKBlue cells in order to measure the activation of the TLR3 signaling pathway (A). Additionally, necrotic fluids were collected from tumor grafts carried by nude or Balb/C mice (B) and from tumor tissues of patients bearing head and neck carcinomas (C). These fluids were also tested on HEKBlue cells in order to measure the activation of the TLR3 signaling pathway.
Techniques Used: Irradiation, Isolation, Activation Assay
Figure Legend Snippet: Figure 2. TLR3 activation in HEKBlue-TLR3 and HEKBlue-null reporter cells after treatment with supernatants from Detroit 562 (A), FaDu (B) and SQ20B cells (C) stressed with irradiation, H2O2, serum deprivation and hypoxia. Ctrl: cells were treated only with fresh culture medium; HY: hypoxia treatment. * p < 0.05, ** p < 0.01, ## p < 0.01 (HEKBlue-TLR3 in relation to HEKBlue-null control), + p < 0.05. (HEKBlue-null in relation to HEKBlue-null control). Statistical significance was determined by t-test.
Techniques Used: Activation Assay, Irradiation, Control
Figure Legend Snippet: Figure 4. Exosome characterization and the treatment of HEKBlue-TLR3 reporter cells with exosomes. Transmission electron microscopy (TEM) images of exosomes derived from Detroit 562, FaDu and SQ20B cell supernatants from control non-irradiated cells and cells after irradiation with 10 Gy (A). Western blot of proteins isolated from exosomes (B) and cell lysate. The loading control is the membrane stained with amido black (C). TLR3 activation after the treatment of HEKBlue-TLR3 cells with exosomes (800 ng) isolated from control non-irradiated cells and cells after irradiation with 10 Gy (D). Comparison between TLR3 activation with crude medium and exosomes isolated after irradiation (E). * p < 0.05, ** p < 0.01, *** p < 0.001.
Techniques Used: Transmission Assay, Electron Microscopy, Derivative Assay, Control, Irradiation, Western Blot, Isolation, Membrane, Staining, Activation Assay, Comparison
Figure Legend Snippet: Figure 5. TLR3 activation after the treatment of HEKBlue-TLR3 and HEKBlue-null cells with necrotic fluids derived from oral squamous cell carcinoma patients: patient 1, patient 2, patient 3, patient 4 and patient 5. Ctrl—cells were treated only with fresh culture medium; RNAse—sample pretreated with RNAse; TLR3ab—sample treated with monoclonal TLR3 antibody; pIC—cells treated with 100 ng/mL poly(I:C). The amount of RNA and protein in each sample is also presented. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001 (HEKBlue-TLR3 in relation to HEKBlue-null control). + p < 0.05 (HEKBlue-null patient in relation to HEKBlue-null control), $ p < 0.05 (HEKBlue-null treatment in relation to HEKBlue-null patient).
Techniques Used: Activation Assay, Derivative Assay, Control
Figure Legend Snippet: Figure 6. TLR3 activation after the treatment of HEKBlue-TLR3 and HEKBlue-null cells with necrotic fluids derived from different mice models: C18, C17 and Renca. Ctrl—cells treated only with medium; RNAse—sample pretreated with RNAse; TLR3ab—sample treated with monoclonal TLR3 antibody; pIC—cells treated with 100 ng/mL poly(I:C). The amount of RNA and protein in each sample is also presented. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.001, ## p < 0.01, ### p < 0.001 (HEKBlue-TLR3 in relation to HEKBlue-null control).
Techniques Used: Activation Assay, Derivative Assay, Control
Related Articles
Incubation:Article Title: The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine Article Snippet: .. After incubation, the supernatant was diluted 1:10 in Article Title: The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. Article Snippet: .. After incubation, the supernatant was diluted 1510 in Expressing:Article Title: The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine Article Snippet: .. After incubation, the supernatant was diluted 1:10 in Article Title: The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. Article Snippet: .. After incubation, the supernatant was diluted 1510 in Suspension:Article Title: The parotid secretory protein BPIFA2 is a salivary surfactant that affects lipopolysaccharide action Article Snippet: LPS activity was detected in saliva or blood plasma using hTLR4-HEK reporter cells (Invivogen, San Diego,CA). .. Samples (20 μl) were mixed with 180 μl cell suspension in |